NZ757220A - Crystalline forms of diazabicyclooctane derivative and production process thereof - Google Patents
Crystalline forms of diazabicyclooctane derivative and production process thereofInfo
- Publication number
- NZ757220A NZ757220A NZ757220A NZ75722014A NZ757220A NZ 757220 A NZ757220 A NZ 757220A NZ 757220 A NZ757220 A NZ 757220A NZ 75722014 A NZ75722014 A NZ 75722014A NZ 757220 A NZ757220 A NZ 757220A
- Authority
- NZ
- New Zealand
- Prior art keywords
- production process
- diazabicyclooctane derivative
- crystalline forms
- diazabicyclooctane
- derivative
- Prior art date
Links
- NFDXQGNDWIPXQL-UHFFFAOYSA-N 1-cyclooctyldiazocane Chemical class C1CCCCCCC1N1NCCCCCC1 NFDXQGNDWIPXQL-UHFFFAOYSA-N 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000013078 crystal Substances 0.000 abstract 2
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013211242 | 2013-10-08 | ||
| NZ743374A NZ743374A (en) | 2013-10-08 | 2014-10-08 | Crystalline forms of diazabicyclooctane derivative and production process thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ757220A true NZ757220A (en) | 2021-12-24 |
Family
ID=52813113
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ757220A NZ757220A (en) | 2013-10-08 | 2014-10-08 | Crystalline forms of diazabicyclooctane derivative and production process thereof |
| NZ743374A NZ743374A (en) | 2013-10-08 | 2014-10-08 | Crystalline forms of diazabicyclooctane derivative and production process thereof |
| NZ757221A NZ757221A (en) | 2013-10-08 | 2014-10-08 | Crystalline forms of diazabicyclooctane derivative and production process thereof |
| NZ757222A NZ757222A (en) | 2013-10-08 | 2014-10-08 | Crystalline forms of diazabicyclooctane derivative and production process thereof |
| NZ719568A NZ719568A (en) | 2013-10-08 | 2014-10-08 | Crystals of diazabicyclooctane derivative and production method for crystals of diazabicyclooctane derivative |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ743374A NZ743374A (en) | 2013-10-08 | 2014-10-08 | Crystalline forms of diazabicyclooctane derivative and production process thereof |
| NZ757221A NZ757221A (en) | 2013-10-08 | 2014-10-08 | Crystalline forms of diazabicyclooctane derivative and production process thereof |
| NZ757222A NZ757222A (en) | 2013-10-08 | 2014-10-08 | Crystalline forms of diazabicyclooctane derivative and production process thereof |
| NZ719568A NZ719568A (en) | 2013-10-08 | 2014-10-08 | Crystals of diazabicyclooctane derivative and production method for crystals of diazabicyclooctane derivative |
Country Status (22)
| Country | Link |
|---|---|
| US (5) | US10131665B2 (enExample) |
| EP (4) | EP3067355B1 (enExample) |
| JP (3) | JP6617029B2 (enExample) |
| KR (2) | KR102487297B1 (enExample) |
| CN (2) | CN111153903A (enExample) |
| AR (4) | AR097971A1 (enExample) |
| AU (1) | AU2014332960B2 (enExample) |
| BR (2) | BR122022016622B1 (enExample) |
| CA (2) | CA2926071C (enExample) |
| DK (1) | DK3067355T3 (enExample) |
| ES (2) | ES2901198T3 (enExample) |
| HK (1) | HK1219479A1 (enExample) |
| HU (1) | HUE051925T2 (enExample) |
| IL (2) | IL244969B (enExample) |
| MX (2) | MX361659B (enExample) |
| MY (1) | MY199066A (enExample) |
| NZ (5) | NZ757220A (enExample) |
| RU (1) | RU2695219C2 (enExample) |
| SG (1) | SG11201602723RA (enExample) |
| TW (1) | TWI673269B (enExample) |
| WO (1) | WO2015053297A1 (enExample) |
| ZA (1) | ZA201602054B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY174523A (en) * | 2012-05-30 | 2020-04-23 | Meiji Seika Pharma Co Ltd | ?-lactamase inhibitor and process for preparing the same |
| MY193210A (en) * | 2013-09-24 | 2022-09-26 | Meiji Seika Pharma Co Ltd | Process for producing diazabicyclooctane derivative |
| WO2015053297A1 (ja) | 2013-10-08 | 2015-04-16 | Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 | ジアザビシクロオクタン誘導体の結晶とその製造法 |
| ES2821826T3 (es) | 2014-12-05 | 2021-04-27 | Meiji Seika Pharma Co Ltd | Método para producir cristales de derivado de diazabiciclooctano y preparación liofilizada estable |
| US10208041B2 (en) * | 2016-10-07 | 2019-02-19 | Hoffman-La Roche Inc. | Diazabicyclooctane compounds |
| CN115745910B (zh) | 2017-07-21 | 2025-05-27 | 安塔比奥公司 | 化学化合物 |
| WO2019064071A1 (en) | 2017-09-27 | 2019-04-04 | F. Hoffmann-La Roche Ag | CRYSTALLINE FORMS OF DIAZABICYCLOOCTANE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF |
| CN111447924A (zh) * | 2017-09-27 | 2020-07-24 | 费多拉制药公司 | 二氮杂二环辛烷衍生物的药物形式及其制备方法 |
| US10584123B2 (en) | 2017-09-27 | 2020-03-10 | Fedora Pharmaceuticals Inc. | Pharmaceutical forms of diazabicyclooctane derivatives and manufacturing method thereof |
| CN107991404B (zh) * | 2017-11-23 | 2021-01-08 | 中山奕安泰医药科技有限公司 | 一种(2s,5r)-苄氧胺基哌啶-2-甲酰胺的检测方法 |
| CN107941944B (zh) * | 2017-11-23 | 2020-09-15 | 中山奕安泰医药科技有限公司 | 一种(2s,5r)-苄氧胺基哌啶-2-甲酸乙酯草酸盐的检测方法 |
| EP3572411A1 (en) | 2018-05-21 | 2019-11-27 | Antabio SAS | Thiazole derivatives as metallo-beta-lactamase inhibitors |
| CN119707784A (zh) * | 2018-09-21 | 2025-03-28 | 株式会社Api | 氨基酸衍生物的制备方法 |
| CN115315298B (zh) * | 2020-07-13 | 2023-09-15 | 日本碍子株式会社 | 精制方法 |
| CN113552250A (zh) * | 2021-06-30 | 2021-10-26 | 海南海灵化学制药有限公司 | 一种盐酸头孢唑兰的杂质检测方法 |
| WO2024263708A2 (en) * | 2023-06-23 | 2024-12-26 | Board Of Trustees Of Michigan State University | Ornithine decarboxylase (odc) inhibitors and uses thereof |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5038509B1 (enExample) | 1970-10-21 | 1975-12-10 | ||
| GB1589317A (en) | 1977-11-24 | 1981-05-13 | Lilly Co Eli | Freeze drying cephalothin sodium |
| JPS6019759B2 (ja) | 1977-11-24 | 1985-05-17 | イ−ライ・リリ−・アンド・カンパニ− | 非経口投予用１１１１５１５２１３９１９９東京都中央区京橋２丁目３番１３号 |
| JPS60255723A (ja) | 1984-05-31 | 1985-12-17 | Ono Pharmaceut Co Ltd | メシル酸ガベキサートの結晶性凍結乾燥製剤及びその製造方法 |
| JPH07117533B2 (ja) | 1985-08-28 | 1995-12-18 | 株式会社生体科学研究所 | トランスフエリンおよびその用途 |
| US20030220521A1 (en) | 1989-07-27 | 2003-11-27 | G.D. Searle & Co. | Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension |
| TW264475B (enExample) | 1991-09-20 | 1995-12-01 | Takeda Pharm Industry Co Ltd | |
| ATE223916T1 (de) | 1994-05-02 | 2002-09-15 | Shionogi & Co | Kristalline pyrrolidylthiocarbapenem derivate, lyophilisierste präparationen dieser kristalle und verfahren zu deren herstellung |
| JP2843444B2 (ja) | 1994-05-02 | 1999-01-06 | 塩野義製薬株式会社 | ピロリジルチオカルバペネム誘導体の結晶，該結晶を含む凍結乾燥製剤，およびその製造方法 |
| DE19531874C1 (de) | 1995-08-30 | 1996-10-02 | Daimler Benz Ag | Seitenwandbaugruppe für eine Kraftfahrzeugkarosserie |
| FR2812635B1 (fr) | 2000-08-01 | 2002-10-11 | Aventis Pharma Sa | Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens |
| FR2825705B1 (fr) | 2001-06-08 | 2005-05-20 | Aventis Pharma Sa | Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens |
| FR2835186B1 (fr) | 2002-01-28 | 2006-10-20 | Aventis Pharma Sa | Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases |
| FR2921060B1 (fr) | 2007-09-14 | 2012-06-15 | Novexel | Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires |
| ES2533826T3 (es) | 2008-01-18 | 2015-04-15 | Merck Sharp & Dohme Corp. | Inhibidores de beta-lactamasa |
| FR2930553B1 (fr) | 2008-04-29 | 2010-05-21 | Novexel | Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases |
| FR2936798B1 (fr) | 2008-10-03 | 2012-09-28 | Novexel | Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens. |
| US20120053350A1 (en) | 2009-04-30 | 2012-03-01 | Ian Mangion | Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids |
| FR2951171A1 (fr) | 2009-10-09 | 2011-04-15 | Novexel | Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation |
| JP2012122603A (ja) | 2010-11-15 | 2012-06-28 | Nifco Inc | コネクタ装置 |
| CN103328476B (zh) | 2010-12-22 | 2016-12-28 | 明治制果药业株式会社 | 光学活性二氮杂环辛烷衍生物及其制备方法 |
| US8772490B2 (en) | 2010-12-22 | 2014-07-08 | Meiji Seika Pharma Co., Ltd. | Optically active diazabicyclooctane derivatives and process for preparing the same |
| JP6023800B2 (ja) * | 2011-06-17 | 2016-11-09 | アストラゼネカ アクチボラグ | ｔｒａｎｓ−７−オキソ−６−（スルホオキシ）−１，６−ジアザビシクロ［３，２，１］オクタン−２−カルボキサミドとその塩が含まれる複素環式化合物を製造するための方法 |
| CA2833241C (en) | 2011-08-27 | 2015-05-12 | Wockhardt Limited | 1,6-diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections |
| PT2872510T (pt) | 2011-08-30 | 2017-03-01 | Wockhardt Ltd | Derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e seu uso no tratamento de infeções bacterianas |
| US8754102B2 (en) | 2011-09-13 | 2014-06-17 | Wockhardt Ltd. | Nitrogen containing compounds and their use |
| US8796257B2 (en) | 2011-12-02 | 2014-08-05 | Naeja Pharmaceutical Inc. | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors |
| US9505761B2 (en) | 2011-12-02 | 2016-11-29 | Fedora Pharmaceuticals Inc. | Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors |
| MY174523A (en) | 2012-05-30 | 2020-04-23 | Meiji Seika Pharma Co Ltd | ?-lactamase inhibitor and process for preparing the same |
| CA2881169C (en) * | 2012-08-25 | 2020-06-16 | Wockhardt Limited | 1,6-diazabicyclo [3,2,1]octan - 7 - one derivatives and their use in the treatment of bacterial infections |
| MY193210A (en) * | 2013-09-24 | 2022-09-26 | Meiji Seika Pharma Co Ltd | Process for producing diazabicyclooctane derivative |
| WO2015053297A1 (ja) | 2013-10-08 | 2015-04-16 | Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 | ジアザビシクロオクタン誘導体の結晶とその製造法 |
| US9688677B1 (en) | 2014-03-29 | 2017-06-27 | Wockhardt Limited | Process for preparation of sodium (2S, 5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylate |
| ES2821826T3 (es) | 2014-12-05 | 2021-04-27 | Meiji Seika Pharma Co Ltd | Método para producir cristales de derivado de diazabiciclooctano y preparación liofilizada estable |
-
2014
- 2014-10-08 WO PCT/JP2014/076875 patent/WO2015053297A1/ja not_active Ceased
- 2014-10-08 TW TW103134993A patent/TWI673269B/zh active
- 2014-10-08 MX MX2016004506A patent/MX361659B/es active IP Right Grant
- 2014-10-08 EP EP14852849.0A patent/EP3067355B1/en active Active
- 2014-10-08 HK HK16107473.3A patent/HK1219479A1/zh unknown
- 2014-10-08 RU RU2016116501A patent/RU2695219C2/ru active
- 2014-10-08 EP EP19202413.1A patent/EP3613741A1/en not_active Withdrawn
- 2014-10-08 JP JP2015541603A patent/JP6617029B2/ja active Active
- 2014-10-08 KR KR1020227012598A patent/KR102487297B1/ko active Active
- 2014-10-08 US US15/027,956 patent/US10131665B2/en active Active
- 2014-10-08 CA CA2926071A patent/CA2926071C/en active Active
- 2014-10-08 KR KR1020167009770A patent/KR102388529B1/ko active Active
- 2014-10-08 SG SG11201602723RA patent/SG11201602723RA/en unknown
- 2014-10-08 DK DK14852849.0T patent/DK3067355T3/da active
- 2014-10-08 EP EP17195437.3A patent/EP3299370B1/en active Active
- 2014-10-08 HU HUE14852849A patent/HUE051925T2/hu unknown
- 2014-10-08 CN CN202010091853.6A patent/CN111153903A/zh active Pending
- 2014-10-08 NZ NZ757220A patent/NZ757220A/en not_active IP Right Cessation
- 2014-10-08 AU AU2014332960A patent/AU2014332960B2/en not_active Ceased
- 2014-10-08 BR BR122022016622-9A patent/BR122022016622B1/pt active IP Right Grant
- 2014-10-08 NZ NZ743374A patent/NZ743374A/en unknown
- 2014-10-08 MX MX2018015407A patent/MX383661B/es unknown
- 2014-10-08 NZ NZ757221A patent/NZ757221A/en unknown
- 2014-10-08 BR BR112016006266-3A patent/BR112016006266B1/pt active IP Right Grant
- 2014-10-08 ES ES17195437T patent/ES2901198T3/es active Active
- 2014-10-08 ES ES14852849T patent/ES2842225T3/es active Active
- 2014-10-08 EP EP19202412.3A patent/EP3613740A1/en not_active Withdrawn
- 2014-10-08 NZ NZ757222A patent/NZ757222A/en unknown
- 2014-10-08 MY MYPI2019007794A patent/MY199066A/en unknown
- 2014-10-08 NZ NZ719568A patent/NZ719568A/en unknown
- 2014-10-08 AR ARP140103759A patent/AR097971A1/es not_active Application Discontinuation
- 2014-10-08 CN CN201480055342.1A patent/CN105612159A/zh active Pending
- 2014-10-08 CA CA3110803A patent/CA3110803C/en active Active
-
2016
- 2016-03-29 ZA ZA2016/02054A patent/ZA201602054B/en unknown
- 2016-04-06 IL IL244969A patent/IL244969B/en unknown
-
2018
- 2018-10-01 US US16/148,774 patent/US10604522B2/en active Active
-
2019
- 2019-09-20 JP JP2019171587A patent/JP6995810B2/ja active Active
-
2020
- 2020-02-18 US US16/793,843 patent/US11414417B2/en active Active
-
2021
- 2021-09-07 JP JP2021145422A patent/JP7182677B2/ja active Active
- 2021-12-22 IL IL289275A patent/IL289275B2/en unknown
-
2022
- 2022-07-07 US US17/859,015 patent/US12221443B2/en active Active
-
2024
- 2024-03-01 AR ARP240100515A patent/AR132028A2/es unknown
- 2024-03-01 AR ARP240100517A patent/AR132030A2/es unknown
- 2024-03-01 AR ARP240100516A patent/AR132029A2/es unknown
- 2024-10-22 US US18/922,948 patent/US20250059191A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ757220A (en) | Crystalline forms of diazabicyclooctane derivative and production process thereof | |
| IL289910A (en) | A method for preparing allulose crystals | |
| MX2022009299A (es) | Derivado de quinolina muy puro y metodo para su produccion. | |
| ZA201907687B (en) | Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same | |
| EP3028994A4 (en) | Silicon carbide powder and method for producing silicon carbide single crystal | |
| EA033455B1 (ru) | Кристаллические формы замещенных 5-фтор-1h-пиразолопиридинов, способы их получения, их применение для получения лекарственного средства, лекарственное средство и способ лечения на их основе | |
| WO2015008218A3 (en) | Process for the preparation of suvorexant and intermediates useful in the synthesis of suvorexant | |
| EP3192898A4 (en) | Method for producing silicon carbide crystals and crystal production device | |
| IN2013MU00646A (enExample) | ||
| MY205261A (en) | Stable crystal form of tipiracil hydrochloride and crystallization method for the same | |
| IL265536A (en) | A method for the production of a crystalline form of the a modification of calcobuterol | |
| UA118550C2 (uk) | Сіль абексиностату, пов'язана з нею кристалічна форма, спосіб її отримання й фармацевтичні композиції, що її містять | |
| WO2015017378A3 (en) | Novel copper-cysteamine and methods of use | |
| PH12015502122A1 (en) | Sovaprevir polymorphs and methods of manufacturing thereof | |
| MX359069B (es) | Sal y formas cristalinas de inhibidor de quinasa tipo polo-4. | |
| AU2014371081A1 (en) | Polyoxalates and a Process for the Production Thereof | |
| AU2016299728A8 (en) | Substituierted Furano-/Thienocycloalkylamino-2-Pyrimidine derivatives and use thereof for controlling undesired plant growth | |
| MY201222A (en) | Synthesis of morin and morin derivatives | |
| WO2016016774A8 (en) | Crystalline forms of canagliflozin | |
| IL231677A (en) | 5-Hydroxy-H1 Crystal-Imidazole-4-Carboxamide 4./3 Hydrate and Method of Manufacturing | |
| IN2014DN08198A (enExample) | ||
| EP3112503A4 (en) | Crucible for crystal growth, crystal growth apparatus provided therewith, and method for growing crystals | |
| AR107441A1 (es) | Forma cristalina de cobicistat | |
| PH12016500261A1 (en) | Nanoparticles and nanoparticle composition, and method for producing nanoparticles and nanoparticle composition | |
| EP3221909A4 (fr) | Reseau d'anatase nanometrique stabilize par des lacunes cationiques, procedes pour leur preparation et leurs utilisations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| LAPS | Patent lapsed |